42148 Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Christopher T. Ritchlin; Philip J. Mease; Wolf-Henning Boehncke; John Tesser; Soumya D. Chakravarty; Emmanouil Rampakakis; May Shawi; Joseph F. Merola; Iain B. McInnes; Atul Deodhar

doi:10.1016/j.jaad.2023.07.903

Back

42148 Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Abstract

Open access

Peer reviewed

42148 Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Christopher T. Ritchlin, Philip J. Mease, Wolf-Henning Boehncke, John Tesser, Soumya D. Chakravarty, Emmanouil Rampakakis, May Shawi, Joseph F. Merola, Iain B. McInnes and Atul Deodhar

Journal of the American Academy of Dermatology, v 89(3), pp AB225-AB225

Sep 2023

DOI: https://doi.org/10.1016/j.jaad.2023.07.903

Files and links (1)

url

https://doi.org/10.1016/j.jaad.2023.07.903View

Published, Version of Record (VoR) Open

Metrics

13 Record Views

Details

Title: 42148 Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Creators: Christopher T. Ritchlin - University of Rochester Medical Center
Philip J. Mease - University of Washington
Wolf-Henning Boehncke - University of Geneva
John Tesser - Arthritis and Rheumatism Associates
Soumya D. Chakravarty - Drexel University
Emmanouil Rampakakis - McGill University
May Shawi - Janssen (United States)
Joseph F. Merola - Brigham and Women's Hospital
Iain B. McInnes - University of Glasgow
Atul Deodhar - Oregon Health & Science University
Publication Details: Journal of the American Academy of Dermatology, v 89(3), pp AB225-AB225
Publisher: Elsevier
Resource Type: Abstract
Language: English
Academic Unit: Rheumatology; General Internal Medicine
Other Identifier: 991021930451104721

42148 Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Files and links (1)

Metrics

Details

Drexel University Social media